Rachel Meyers Teriflunomide isn't the toughest comparator out there, would like to see how remibrutinib stacks up against some of the stronger existing MS drugs before getting too excited.
Sam Okafor Good to see multiple companies like GRIN Therapeutics also active at this congress, feels like real momentum building in the rare epilepsy space.